Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2000-06-20

AUTHORS

A Ohtsu, H Baba, Y Sakata, Y Mitachi, N Horikoshi, K Sugimachi, T Taguchi

ABSTRACT

This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD). Sixty-three patients with measurable metastatic colorectal carcinoma were enrolled into the study. None of the patients had received prior chemotherapy except for adjuvant setting. S-1 was administered orally twice daily at a standard dose of 80 mg m–2day–1for 28 days followed by a 14-day rest. This agent is continued until disease progression, unaccepted toxicity, or patient refusal. Twenty-two (35%) of the 62 eligible patients achieved PR with a 95% confidence interval of 25–48%. Five of the 10 patients with a history of adjuvant chemotherapy achieved partial remission. The median survival time was 12 months. Major adverse reactions included myelosuppressive and gastrointestinal toxicities, though their incidence of grade 3 or 4 being 13% in neutropenia and less than 10% in the others. None of the 53 patients treated as outpatients required hospitalization due to adverse reactions: These results suggest that S-1 achieves similar responses to those of infusional 5-FU plus leucovorin and shows the potential of another biochemical modulation with easily manageable toxicity. © 2000 Cancer Research Campaign More... »

PAGES

141-145

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1054/bjoc.2000.1236

DOI

http://dx.doi.org/10.1054/bjoc.2000.1236

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1051473356

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10901361


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxonic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tegafur", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Gastrointestinal Oncology/Gastroenterology, National Cancer Center Hospital East, Kashiwa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.497282.2", 
          "name": [
            "Department of Gastrointestinal Oncology/Gastroenterology, National Cancer Center Hospital East, Kashiwa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ohtsu", 
        "givenName": "A", 
        "id": "sg:person.0770022576.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770022576.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterologic Surgery, National Kyushu Cancer Center, Fukuoka, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Gastroenterologic Surgery, National Kyushu Cancer Center, Fukuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baba", 
        "givenName": "H", 
        "id": "sg:person.011555637362.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011555637362.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Aomori Prefectural Central Hospital, Aomori, Japan", 
          "id": "http://www.grid.ac/institutes/grid.413825.9", 
          "name": [
            "Department of Gastroenterology, Aomori Prefectural Central Hospital, Aomori, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakata", 
        "givenName": "Y", 
        "id": "sg:person.011653372052.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011653372052.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology and Medical Oncology, Sendai Kosei Hospital, Miyagi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415501.4", 
          "name": [
            "Department of Gastroenterology and Medical Oncology, Sendai Kosei Hospital, Miyagi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mitachi", 
        "givenName": "Y", 
        "id": "sg:person.01135467016.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135467016.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chemotherapy Cancer Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410807.a", 
          "name": [
            "Chemotherapy Cancer Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Horikoshi", 
        "givenName": "N", 
        "id": "sg:person.01217531417.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217531417.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.177174.3", 
          "name": [
            "Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sugimachi", 
        "givenName": "K", 
        "id": "sg:person.01024215256.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024215256.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Japan Society for Cancer Chemotherapy, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Japan Society for Cancer Chemotherapy, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Taguchi", 
        "givenName": "T", 
        "id": "sg:person.016552720302.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016552720302.09"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s002800050561", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028328879", 
          "https://doi.org/10.1007/s002800050561"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1990.431", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019067252", 
          "https://doi.org/10.1038/bjc.1990.431"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2000-06-20", 
    "datePublishedReg": "2000-06-20", 
    "description": "This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD). Sixty-three patients with measurable metastatic colorectal carcinoma were enrolled into the study. None of the patients had received prior chemotherapy except for adjuvant setting. S-1 was administered orally twice daily at a standard dose of 80 mg m\u20132day\u20131for 28 days followed by a 14-day rest. This agent is continued until disease progression, unaccepted toxicity, or patient refusal. Twenty-two (35%) of the 62 eligible patients achieved PR with a 95% confidence interval of 25\u201348%. Five of the 10 patients with a history of adjuvant chemotherapy achieved partial remission. The median survival time was 12 months. Major adverse reactions included myelosuppressive and gastrointestinal toxicities, though their incidence of grade 3 or 4 being 13% in neutropenia and less than 10% in the others. None of the 53 patients treated as outpatients required hospitalization due to adverse reactions: These results suggest that S-1 achieves similar responses to those of infusional 5-FU plus leucovorin and shows the potential of another biochemical modulation with easily manageable toxicity. \u00a9 2000 Cancer Research Campaign", 
    "genre": "article", 
    "id": "sg:pub.10.1054/bjoc.2000.1236", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "83"
      }
    ], 
    "keywords": [
      "metastatic colorectal carcinoma", 
      "adverse reactions", 
      "colorectal carcinoma", 
      "biochemical modulation", 
      "dihydropyrimidine dehydrogenase", 
      "measurable metastatic colorectal carcinoma", 
      "major adverse reactions", 
      "median survival time", 
      "prior chemotherapy", 
      "adjuvant setting", 
      "eligible patients", 
      "adjuvant chemotherapy", 
      "manageable toxicity", 
      "partial remission", 
      "gastrointestinal toxicity", 
      "potassium oxonate", 
      "standard dose", 
      "patient refusal", 
      "disease progression", 
      "grade 3", 
      "survival time", 
      "patients", 
      "confidence intervals", 
      "chemotherapy", 
      "carcinoma", 
      "toxicity", 
      "similar responses", 
      "remission", 
      "neutropenia", 
      "leucovorin", 
      "hospitalization", 
      "outpatients", 
      "oxonate", 
      "tegafur", 
      "incidence", 
      "dose", 
      "progression", 
      "months", 
      "efficacy", 
      "modulation", 
      "inhibition", 
      "study", 
      "days", 
      "agents", 
      "setting", 
      "response", 
      "interval", 
      "refusal", 
      "rest", 
      "dehydrogenase", 
      "history", 
      "dihydroxypyridine", 
      "PR", 
      "reaction", 
      "time", 
      "potential", 
      "results"
    ], 
    "name": "Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma", 
    "pagination": "141-145", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1051473356"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1054/bjoc.2000.1236"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10901361"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1054/bjoc.2000.1236", 
      "https://app.dimensions.ai/details/publication/pub.1051473356"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_315.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1054/bjoc.2000.1236"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1054/bjoc.2000.1236'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1054/bjoc.2000.1236'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1054/bjoc.2000.1236'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1054/bjoc.2000.1236'


 

This table displays all metadata directly associated to this object as RDF triples.

249 TRIPLES      21 PREDICATES      100 URIs      90 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1054/bjoc.2000.1236 schema:about N3dc9e52ce80e40f88db23bef9db9a258
2 N45058b1543684e91810f4b2792239fc8
3 N5a4bef7a7d0c4ef498b10e81ae2f313e
4 N5d085305194b4c378e49336b7b5f7e2f
5 N5eb2f18506bc4e36ab770a023cedcf8f
6 N6bd59b1a606441f3bd7d2a82d0e17ebe
7 N80d4f3809ab342059e28f24ae4a26f8f
8 N8be988ff0a41470792c374aeacebfb52
9 N9de6cceb51ab48e39cb75e24e4cc650c
10 N9ef85676c92d4b20a1b703225a119777
11 Nce4cd02e8e214b8da2c2bbc9cffb5914
12 Nd074f5dbe1654db98bc1269fb4df60a9
13 Ne0664385f3464cdb994964293d3bbd82
14 Neddba591adf947eab1440366b1425492
15 Nede222c9d0c1460c863592700ada36bb
16 Nfea553cf927f4a92b564b1ab6ca67705
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author Nce6de4daab944f688d263e1ca887ad03
20 schema:citation sg:pub.10.1007/s002800050561
21 sg:pub.10.1038/bjc.1990.431
22 schema:datePublished 2000-06-20
23 schema:datePublishedReg 2000-06-20
24 schema:description This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD). Sixty-three patients with measurable metastatic colorectal carcinoma were enrolled into the study. None of the patients had received prior chemotherapy except for adjuvant setting. S-1 was administered orally twice daily at a standard dose of 80 mg m–2day–1for 28 days followed by a 14-day rest. This agent is continued until disease progression, unaccepted toxicity, or patient refusal. Twenty-two (35%) of the 62 eligible patients achieved PR with a 95% confidence interval of 25–48%. Five of the 10 patients with a history of adjuvant chemotherapy achieved partial remission. The median survival time was 12 months. Major adverse reactions included myelosuppressive and gastrointestinal toxicities, though their incidence of grade 3 or 4 being 13% in neutropenia and less than 10% in the others. None of the 53 patients treated as outpatients required hospitalization due to adverse reactions: These results suggest that S-1 achieves similar responses to those of infusional 5-FU plus leucovorin and shows the potential of another biochemical modulation with easily manageable toxicity. © 2000 Cancer Research Campaign
25 schema:genre article
26 schema:isAccessibleForFree true
27 schema:isPartOf N1416d3d33d2f4d9e856726d2b0dfed7c
28 N6029e0fc039c4a3faac8531faacdd830
29 sg:journal.1017082
30 schema:keywords PR
31 adjuvant chemotherapy
32 adjuvant setting
33 adverse reactions
34 agents
35 biochemical modulation
36 carcinoma
37 chemotherapy
38 colorectal carcinoma
39 confidence intervals
40 days
41 dehydrogenase
42 dihydropyrimidine dehydrogenase
43 dihydroxypyridine
44 disease progression
45 dose
46 efficacy
47 eligible patients
48 gastrointestinal toxicity
49 grade 3
50 history
51 hospitalization
52 incidence
53 inhibition
54 interval
55 leucovorin
56 major adverse reactions
57 manageable toxicity
58 measurable metastatic colorectal carcinoma
59 median survival time
60 metastatic colorectal carcinoma
61 modulation
62 months
63 neutropenia
64 outpatients
65 oxonate
66 partial remission
67 patient refusal
68 patients
69 potassium oxonate
70 potential
71 prior chemotherapy
72 progression
73 reaction
74 refusal
75 remission
76 response
77 rest
78 results
79 setting
80 similar responses
81 standard dose
82 study
83 survival time
84 tegafur
85 time
86 toxicity
87 schema:name Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma
88 schema:pagination 141-145
89 schema:productId N02c196821aa34ac38da0549609abf316
90 N304f2856c51247c0abd5c2514c83d7df
91 Ncd0936f327a44e79b6f01525ef1bcc26
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051473356
93 https://doi.org/10.1054/bjoc.2000.1236
94 schema:sdDatePublished 2022-10-01T06:30
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher N0053179e49864d6e8d6cc83093f1e71d
97 schema:url https://doi.org/10.1054/bjoc.2000.1236
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N0053179e49864d6e8d6cc83093f1e71d schema:name Springer Nature - SN SciGraph project
102 rdf:type schema:Organization
103 N02c196821aa34ac38da0549609abf316 schema:name pubmed_id
104 schema:value 10901361
105 rdf:type schema:PropertyValue
106 N1416d3d33d2f4d9e856726d2b0dfed7c schema:volumeNumber 83
107 rdf:type schema:PublicationVolume
108 N257fccbb6d384084b6c0778c5bb2725d rdf:first sg:person.016552720302.09
109 rdf:rest rdf:nil
110 N2bed70da68284838a130c6821acf0d6e rdf:first sg:person.01135467016.12
111 rdf:rest Na0a45ac7f97c41b29a8d3e6989011d01
112 N304f2856c51247c0abd5c2514c83d7df schema:name dimensions_id
113 schema:value pub.1051473356
114 rdf:type schema:PropertyValue
115 N3dc9e52ce80e40f88db23bef9db9a258 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Pyridines
117 rdf:type schema:DefinedTerm
118 N45058b1543684e91810f4b2792239fc8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Treatment Outcome
120 rdf:type schema:DefinedTerm
121 N5a4bef7a7d0c4ef498b10e81ae2f313e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Colorectal Neoplasms
123 rdf:type schema:DefinedTerm
124 N5cf3ee2a35e84929b14df45b4f4e81f3 rdf:first sg:person.011555637362.26
125 rdf:rest N8ebb2e1af2a2444685be299978593595
126 N5d085305194b4c378e49336b7b5f7e2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Humans
128 rdf:type schema:DefinedTerm
129 N5eb2f18506bc4e36ab770a023cedcf8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Tegafur
131 rdf:type schema:DefinedTerm
132 N6029e0fc039c4a3faac8531faacdd830 schema:issueNumber 2
133 rdf:type schema:PublicationIssue
134 N6bd59b1a606441f3bd7d2a82d0e17ebe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Middle Aged
136 rdf:type schema:DefinedTerm
137 N80d4f3809ab342059e28f24ae4a26f8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Administration, Oral
139 rdf:type schema:DefinedTerm
140 N8be988ff0a41470792c374aeacebfb52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Antimetabolites, Antineoplastic
142 rdf:type schema:DefinedTerm
143 N8ebb2e1af2a2444685be299978593595 rdf:first sg:person.011653372052.41
144 rdf:rest N2bed70da68284838a130c6821acf0d6e
145 N9de6cceb51ab48e39cb75e24e4cc650c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Female
147 rdf:type schema:DefinedTerm
148 N9ef85676c92d4b20a1b703225a119777 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Neoplasm Metastasis
150 rdf:type schema:DefinedTerm
151 Na0a45ac7f97c41b29a8d3e6989011d01 rdf:first sg:person.01217531417.84
152 rdf:rest Nfcd87890207d4659998895c600c48e5d
153 Ncd0936f327a44e79b6f01525ef1bcc26 schema:name doi
154 schema:value 10.1054/bjoc.2000.1236
155 rdf:type schema:PropertyValue
156 Nce4cd02e8e214b8da2c2bbc9cffb5914 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Aged
158 rdf:type schema:DefinedTerm
159 Nce6de4daab944f688d263e1ca887ad03 rdf:first sg:person.0770022576.74
160 rdf:rest N5cf3ee2a35e84929b14df45b4f4e81f3
161 Nd074f5dbe1654db98bc1269fb4df60a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Survival Rate
163 rdf:type schema:DefinedTerm
164 Ne0664385f3464cdb994964293d3bbd82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Oxonic Acid
166 rdf:type schema:DefinedTerm
167 Neddba591adf947eab1440366b1425492 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Adult
169 rdf:type schema:DefinedTerm
170 Nede222c9d0c1460c863592700ada36bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Drug Combinations
172 rdf:type schema:DefinedTerm
173 Nfcd87890207d4659998895c600c48e5d rdf:first sg:person.01024215256.70
174 rdf:rest N257fccbb6d384084b6c0778c5bb2725d
175 Nfea553cf927f4a92b564b1ab6ca67705 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Male
177 rdf:type schema:DefinedTerm
178 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
179 schema:name Medical and Health Sciences
180 rdf:type schema:DefinedTerm
181 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
182 schema:name Oncology and Carcinogenesis
183 rdf:type schema:DefinedTerm
184 sg:journal.1017082 schema:issn 0007-0920
185 1532-1827
186 schema:name British Journal of Cancer
187 schema:publisher Springer Nature
188 rdf:type schema:Periodical
189 sg:person.01024215256.70 schema:affiliation grid-institutes:grid.177174.3
190 schema:familyName Sugimachi
191 schema:givenName K
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024215256.70
193 rdf:type schema:Person
194 sg:person.01135467016.12 schema:affiliation grid-institutes:grid.415501.4
195 schema:familyName Mitachi
196 schema:givenName Y
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135467016.12
198 rdf:type schema:Person
199 sg:person.011555637362.26 schema:affiliation grid-institutes:None
200 schema:familyName Baba
201 schema:givenName H
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011555637362.26
203 rdf:type schema:Person
204 sg:person.011653372052.41 schema:affiliation grid-institutes:grid.413825.9
205 schema:familyName Sakata
206 schema:givenName Y
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011653372052.41
208 rdf:type schema:Person
209 sg:person.01217531417.84 schema:affiliation grid-institutes:grid.410807.a
210 schema:familyName Horikoshi
211 schema:givenName N
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217531417.84
213 rdf:type schema:Person
214 sg:person.016552720302.09 schema:affiliation grid-institutes:None
215 schema:familyName Taguchi
216 schema:givenName T
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016552720302.09
218 rdf:type schema:Person
219 sg:person.0770022576.74 schema:affiliation grid-institutes:grid.497282.2
220 schema:familyName Ohtsu
221 schema:givenName A
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770022576.74
223 rdf:type schema:Person
224 sg:pub.10.1007/s002800050561 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028328879
225 https://doi.org/10.1007/s002800050561
226 rdf:type schema:CreativeWork
227 sg:pub.10.1038/bjc.1990.431 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019067252
228 https://doi.org/10.1038/bjc.1990.431
229 rdf:type schema:CreativeWork
230 grid-institutes:None schema:alternateName Department of Gastroenterologic Surgery, National Kyushu Cancer Center, Fukuoka, Japan
231 Japan Society for Cancer Chemotherapy, Osaka, Japan
232 schema:name Department of Gastroenterologic Surgery, National Kyushu Cancer Center, Fukuoka, Japan
233 Japan Society for Cancer Chemotherapy, Osaka, Japan
234 rdf:type schema:Organization
235 grid-institutes:grid.177174.3 schema:alternateName Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan
236 schema:name Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan
237 rdf:type schema:Organization
238 grid-institutes:grid.410807.a schema:alternateName Chemotherapy Cancer Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
239 schema:name Chemotherapy Cancer Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
240 rdf:type schema:Organization
241 grid-institutes:grid.413825.9 schema:alternateName Department of Gastroenterology, Aomori Prefectural Central Hospital, Aomori, Japan
242 schema:name Department of Gastroenterology, Aomori Prefectural Central Hospital, Aomori, Japan
243 rdf:type schema:Organization
244 grid-institutes:grid.415501.4 schema:alternateName Department of Gastroenterology and Medical Oncology, Sendai Kosei Hospital, Miyagi, Japan
245 schema:name Department of Gastroenterology and Medical Oncology, Sendai Kosei Hospital, Miyagi, Japan
246 rdf:type schema:Organization
247 grid-institutes:grid.497282.2 schema:alternateName Department of Gastrointestinal Oncology/Gastroenterology, National Cancer Center Hospital East, Kashiwa, Japan
248 schema:name Department of Gastrointestinal Oncology/Gastroenterology, National Cancer Center Hospital East, Kashiwa, Japan
249 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...